CNCR vs. XBI
Compare and contrast key facts about Loncar Cancer Immunotherapy ETF (CNCR) and SPDR S&P Biotech ETF (XBI).
CNCR and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both CNCR and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CNCR or XBI.
Correlation
The correlation between CNCR and XBI is 0.86, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
CNCR vs. XBI - Performance Comparison
Key characteristics
CNCR:
-0.65
XBI:
-0.03
CNCR:
-0.78
XBI:
0.13
CNCR:
0.92
XBI:
1.02
CNCR:
-0.35
XBI:
-0.01
CNCR:
-1.14
XBI:
-0.07
CNCR:
20.19%
XBI:
9.38%
CNCR:
35.59%
XBI:
24.40%
CNCR:
-72.14%
XBI:
-63.89%
CNCR:
-62.11%
XBI:
-46.72%
Returns By Period
In the year-to-date period, CNCR achieves a 2.11% return, which is significantly lower than XBI's 2.74% return.
CNCR
2.11%
3.71%
-14.95%
-20.69%
-9.55%
N/A
XBI
2.74%
5.18%
-9.11%
0.31%
-0.92%
2.85%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
CNCR vs. XBI - Expense Ratio Comparison
CNCR has a 0.79% expense ratio, which is higher than XBI's 0.35% expense ratio.
Risk-Adjusted Performance
CNCR vs. XBI — Risk-Adjusted Performance Rank
CNCR
XBI
CNCR vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
CNCR vs. XBI - Dividend Comparison
CNCR has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.14%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% | 7.79% | 0.91% | 0.00% | 0.00% | 1.47% | 0.00% | 0.37% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.14% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% |
Drawdowns
CNCR vs. XBI - Drawdown Comparison
The maximum CNCR drawdown since its inception was -72.14%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for CNCR and XBI. For additional features, visit the drawdowns tool.
Volatility
CNCR vs. XBI - Volatility Comparison
Loncar Cancer Immunotherapy ETF (CNCR) has a higher volatility of 9.17% compared to SPDR S&P Biotech ETF (XBI) at 5.62%. This indicates that CNCR's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.